Department of Pharmacology, College of Korean Medicine, Sangji University, Wonju 26339, Korea.
Department of Internal Medicine of Korean Medicine, Oriental Medicine Hospital of Sangji University, Wonju 26338, Korea.
Nutrients. 2021 Aug 27;13(9):2992. doi: 10.3390/nu13092992.
Obesity remains a continuing global health concern, as it is associated with an increased risk of many chronic diseases. Koidz. (Ac) is traditionally used in the treatment of inflammatory diseases, such as arthritis, hepatitis, and gastric ulcers. Despite the diverse pharmacological activities of Ac, scientific evidence for the use of Ac in obesity is still limited. Therefore, the present study aimed to determine the anti-obesity effects of Ac. C57BL/6N mice were divided into five groups as follows: chow diet group (CON), 45% HFD group, HFD + oral administration of orlistat group, and HFD + oral administration of Ac groups. RT-PCR and western blotting were used to examine the expression of molecules relating to obesity progression. Ac-administered mice showed dramatically decreased body weight and weight gain compared to the high-fat diet (HFD)-fed mice. In addition, Ac administration attenuated the protein expression levels of adipogenic transcription factors in the white adipose tissue (WAT) and livers of HFD-fed mice. Furthermore, Ac administration declined the expression levels of lipogenic genes, while enhancing those of the fatty acid oxidation genes in the WAT of HFD-fed mice. Importantly, Ac administration highly upregulated the AMP-activated kinase (AMPK) and sirtuin 1 (SIRT1) expression levels in WAT of the HFD-induced obese mouse model. Our results provide evidence that Ac can effectively ameliorate weight gain and adipose tissue expansion.
肥胖仍然是一个持续存在的全球健康问题,因为它与许多慢性疾病的风险增加有关。Koidz.(Ac)传统上用于治疗炎症性疾病,如关节炎、肝炎和胃溃疡。尽管 Ac 具有多种药理学活性,但将 Ac 用于肥胖的科学证据仍然有限。因此,本研究旨在确定 Ac 的抗肥胖作用。将 C57BL/6N 小鼠分为五组:标准饮食组(CON)、45%高脂肪饮食组(HFD)、HFD+奥利司他口服组和 HFD+Ac 口服组。使用 RT-PCR 和 Western blot 检测与肥胖进展相关的分子的表达。与高脂肪饮食(HFD)喂养的小鼠相比,给予 Ac 的小鼠体重和体重增加明显下降。此外,Ac 给药可减轻 HFD 喂养小鼠白色脂肪组织(WAT)和肝脏中脂肪生成转录因子的蛋白表达水平。此外,Ac 给药降低了 HFD 喂养小鼠 WAT 中脂肪生成基因的表达水平,同时增强了脂肪酸氧化基因的表达水平。重要的是,Ac 给药可显著上调 HFD 诱导肥胖小鼠模型 WAT 中的 AMP 激活的蛋白激酶(AMPK)和 SIRT1 表达水平。我们的结果提供了证据表明 Ac 可以有效改善体重增加和脂肪组织扩张。